Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa
Vaccine·
- DOI
- 10.1016/j.vaccine.2016.11.042
- PMID
- 27890400
- PMCID
- —
- OpenAlex
- W2553284277
- Study type
- Randomised controlled trial
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The paper is relevant to malaria vaccine policy because it supports country adoption discussions by summarizing projected burden reduction and cost-effectiveness under specified assumptions. It also notes that feasibility, scaling, and delivery constraints matter for implementation.
Structured evidence summary
Research question
To estimate the country-level impact and cost-effectiveness of introducing the RTS,S/AS01 malaria vaccine across endemic African countries.
Study design
A country-level modeling study using an ensemble of malaria epidemiology models, informed by 32-month phase 3 trial follow-up data, with sensitivity analyses on vaccine, transmission, and economic inputs. The metadata labels it as a randomized controlled trial, but the abstract itself describes model-based predictions.
Population and setting
Endemic Africa, specifically 43 countries, with outcomes reported for children receiving a four-dose RTS,S/AS01 schedule alongside routine malaria control.
Main findings
The model projected that implementation in all 43 countries could avert about 123 million malaria episodes over 10 years. It estimated an average of 18,413 DALYs averted per 100,000 fully vaccinated children, with wide between-country variation, and a median cost-effectiveness ratio of $188 per DALY averted at $5 per dose.
Public-health relevance
The paper is relevant to malaria vaccine policy because it supports country adoption discussions by summarizing projected burden reduction and cost-effectiveness under specified assumptions. It also notes that feasibility, scaling, and delivery constraints matter for implementation.
Important limitations
The results depend on modeled assumptions about vaccine price, coverage, vaccine properties, transmission, and economic inputs, and the abstract highlights operational constraints in reaching children at risk. This summary is limited to the supplied single-article abstract and metadata; the original paper is needed for decision-grade interpretation.
GIDS interpretation
This article is discoverable as a peer-reviewed modeling and economic evaluation of a malaria vaccine in endemic Africa. It provides context for RTS,S/AS01 policy assessment, but it should not be treated as live surveillance evidence or a confirmed signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 7 auditable classifier relationships to diseases, places, topics, and study design.